From the Helm: Poised for a breakthrough – Immutep CEO Marc Voigt

Jessica Amir
March 16, 2020

In the latest instalment of Bell Direct’s From the Helm series, Jess speaks with Immutep’s CEO Marc Voigt.

What areas in healthcare do Immutep (ASX:IMM) compete in? Marc explains Immutep’s hand in immuno-oncology and immunotherapy, and how their range of products help save lives. How is the Immutep metastatic breast cancer treatment potentially going to shape the world of immuno-oncology treatments in breast cancer? What would the success of these clinical trials mean for business?

Plus, a quick word on COVID-19 and its impacts on the business.

Morning Bell 15 July

Jessica Amir
July 15, 2020

Morning Bell 14 July

Jessica Amir
July 14, 2020

Morning Bell 13 July

Jessica Amir
July 13, 2020

Weekly Wrap 10 July

Jessica Amir
July 10, 2020

Morning Bell 10 July

Jessica Amir
July 10, 2020

Morning Bell 9 July

Jessica Amir
July 9, 2020

Morning Bell 8 July

Jessica Amir
July 8, 2020

Morning Bell 7 July

Jessica Amir
July 7, 2020

Morning Bell 6 July

Jessica Amir
July 6, 2020

Weekly Wrap 3 July

Jessica Amir
July 3, 2020

Morning Bell 3 July

Jessica Amir
July 3, 2020